Pricing Log in Create free account
Friday 6 November 2026 Export RDY’s income statement to Excel — free account

Dr. Reddy's Laboratories Ltd

RDY Healthcare Drug Manufacturers Specialty & Generic

Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.

Revenue
−10.1%
EPS
−36.8%
Free cash flow
−70.5%
Total debt
+14.1%

Quarter to September 2026, against a year earlier

14.53 0.24 −1.62%
Market cap
$12.1B
P/E
44.4×
Fwd P/E
30.7×
Dividend yield
0.00%
F-score
4/9
Altman Z
5.26
Beneish M
−2.59
Dividend safety
74/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Dr. Reddy's Laboratories Ltd (RDY) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Dr. Reddy's Laboratories Ltd (RDY) trades at a EV/EBITDA of 22.9×. Over the past ten years it has ranged from 9.7× (May 2023) to 67.1× (October 2024); the current reading is higher than 98% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2026 15.0× 44.46%
FY2025 10.4× (10.89%)
FY2024 11.7× 12.05%
FY2023 10.4× (37.44%)
FY2022 16.7× 2.91%
FY2021 16.2× 46.68%
FY2020 11.0× (23.72%)
FY2019 14.5× (9.81%)
FY2018 16.1× (14.43%)
FY2017 18.8× 48.40%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 19.9× 5.25%
Jun 2026 18.9× 25.45%
Mar 2026 15.0× 28.47%
Dec 2025 11.7× 6.02%
43 more quarters

Against its own ten years

Low 9.7× High 67.1×
Ten-year median 14.6×
Current reading's percentile 98

EV/EBITDA against peers

Company EV/EBITDA
HIMS Hims & Hers Health, Inc. compare n/m
VTRS Viatris Inc. compare 12.3×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 14.3×
NBIX Neurocrine Biosciences, Inc. compare 16.5×
LNTH Lantheus Holdings, Inc. compare 16.7×
ELAN Elanco Animal Health Incorporated compare 19.7×
RDY Dr. Reddy's Laboratories Ltd 22.9×
ALKS Alkermes plc compare 37.9×
KNSA Kiniksa Pharmaceuticals International, plc compare 48.0×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on RDY